• Five cohorts in Nyrada's Phase I clinical trial successfully completed with no safety signals
• Preclinical studies showed Xolatryp provided neuroprotection and cardioprotection
• Phase IIa trial planned for Xolatryp targeting patients with acute myocardial infarction

Nyrada Inc. (ASX:NYR), a clinical stage drug discovery and development company, has announced its Quarterly Activities Report and Appendix 4C for the three-month period ending 30 June 2025. The highlights include the successful completion of five cohorts in Nyrada's Phase I clinical trial of its lead drug candidate Xolatryp, with no safety signals, dose-limiting toxicities, or unexpected side effects reported. The trial's Safety Review Committee also approved the amendment of the Phase I protocol to enable the assessment of Xolatryp's safety and tolerability at higher doses and longer durations. Nyrada also reported positive preclinical results, including a statistically significant neuroprotective effect of Xolatryp in a traumatic brain injury study, and 42% cardioprotection with reduced incidence of arrhythmia in a coronary heart disease study. The company plans to commence a Phase IIa clinical trial of Xolatryp targeting patients with acute myocardial infarction in the quarter ending March 2026. Nyrada ended the quarter with a cash position of AU$2.93 million.

Nyrada plans to commence a Phase IIa clinical trial of Xolatryp targeting patients with acute myocardial infarction in the quarter ending March 2026, with the trial expected to continue for six to nine months.

Nyrada is focused on the continued development of its lead drug candidate Xolatryp, with plans to commence a Phase IIa clinical trial targeting acute myocardial infarction patients in the near future. The company is also exploring the potential of Xolatryp in other indications, such as traumatic brain injury and coronary heart disease, based on the positive preclinical results.